Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: Acute kidney injury (AKI) is a common complication of sepsis associated with increased risk of death. Preclinical data and observational human studies suggest that activation of AMP-activated protein kinase, an ubiquitous master regulator of energy that can limit mitochondrial injury, with metformin may protect against sepsis-associated AKI (SA-AKI) and mortality. The Randomized Clinical Trial of the Safety and FeasibiLity of Metformin as a Treatment for sepsis-associated AKI (LiMiT AKI) aims to evaluate the safety and feasibility of enteral metformin in patients with sepsis at risk of developing SA-AKI.
Methods And Analysis: Blind, randomised, placebo-controlled clinical trial in a single-centre, quaternary teaching hospital in the USA. We will enrol adult patients (18 years of age or older) within 48 hours of meeting Sepsis-3 criteria, admitted to intensive care unit, with oral or enteral access. Patients will be randomised 1:1:1 to low-dose metformin (500 mg two times per day), high-dose metformin (1000 mg two times per day) or placebo for 5 days. Primary safety outcome will be the proportion of metformin-associated serious adverse events. Feasibility assessment will be based on acceptability by patients and clinicians, and by enrolment rate.
Ethics And Dissemination: This study has been approved by the Institutional Review Board. All patients or surrogates will provide written consent prior to enrolment and any study intervention. Metformin is a widely available, inexpensive medication with a long track record for safety, which if effective would be accessible and easy to deploy. We describe the study methods using the Standard Protocol Items for Randomized Trials framework and discuss key design features and methodological decisions. LiMiT AKI will investigate the feasibility and safety of metformin in critically ill patients with sepsis at risk of SA-AKI, in preparation for a future large-scale efficacy study. Main results will be published as soon as available after final analysis.
Trial Registration Number: NCT05900284.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11086423 | PMC |
| http://dx.doi.org/10.1136/bmjopen-2023-081120 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Validation of plasma microRNAs as biomarkers in sepsis associated acute kidney injury upon first clinical presentation reveals limited diagnostic and prognostic performance.
PLoS One
September 2025
Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Background: Sepsis is a life-threatening response to an infection, often complicated by sepsis-associated acute kidney injury (SA-AKI). Early recognition of SA-AKI is critical but challenged by the limited sensitivity of existing diagnostic markers. MicroRNAs (miRNAs), which regulate key SA-AKI pathways, have shown diagnostic promise, yet their clinical utility in early SA-AKI recognition remains unexplored.
View Article and Find Full Text PDFUncovering molecular markers of the microvascular endothelial response in sepsis-associated acute kidney injury: a translational study in mice and humans.
Intensive Care Med Exp
September 2025
Department of Pathology and Medical Biology, Medical Biology section, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Introduction: Endothelial cells play a central role in the pathophysiology of sepsis-associated acute kidney injury (SA-AKI), yet we have limited understanding of the markers of microvascular-specific response. We therefore employed a translational approach integrating spatially resolved transcriptomics in a mouse SA-AKI model with validation in human kidney tissues and plasma, aiming to define the molecular signature of the endothelial response to SA-AKI in mice and in human patients.
Methods: In this post hoc analysis of prospectively collected data, we identified sepsis-associated target mRNAs and validated their expression via RT-qPCR in distinct renal microvascular compartments isolated by laser microdissection (LMD) from both cecal ligation and puncture (CLP) mice and post-mortem kidney biopsies of SA-AKI patients.
Early body temperature trajectories and short term prognosis in sepsis associated acute kidney injury.
Sci Rep
August 2025
Emergency Department, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.
To explore the associations between temperature trajectories and in-hospital mortality and renal replacement therapy in patients with sepsis-associated acute kidney injury (SA-AKI). By using data from the Medical Information Mart for Intensive Care (MIMIC)-IV, participants were divided into three groups (≤ 36 °C, 36-38 °C, ≥ 38 °C). We identified body temperature trajectories by a latent class mixed model and explored the associations of these trajectories with in-hospital mortality using Cox hazard proportional regression models, further exploring the associations with renal replacement therapy using logistic regression models.
View Article and Find Full Text PDFCirculating angiotensin-converting enzyme 2 concentration is associated with acute kidney injury and mortality in sepsis.
PLoS One
August 2025
Institute of Clinical Medicine, National Yang-Ming Chiao-Tung University, Taipei, Taiwan.
Background: Beyond the well-established classical renin-angiotensin system (RAS), emerging evidence highlights the critical role of the non-classical RAS, specifically the Angiotensin (1-7)/ACE2/Mas axis. As the key enzyme converting Angiotensin II into Angiotensin (1-7), angiotensin-converting enzyme 2 (ACE2) exerts cardioprotective and anti-inflammatory effects, showing potential therapeutic value in critical care. This study investigates the association between circulating ACE2 levels and clinical outcomes in sepsis, offering insights into its role and potential for predicting sepsis outcomes.
View Article and Find Full Text PDFNeutrophil Gelatinase-Related Lipocalin and Renal Resistive Index in the Diagnosis and Prognosis of Sepsis-Associated Acute Kidney Injury: A Cross-Sectional Study from Türkiye.
Niger J Clin Pract
August 2025
Department of Anesthesiology and Reanimation, Intensive Care Unit, Inonu University, Malatya, Turkiye.
Background: Acute kidney injury (AKI) is common in intensive care unit (ICU) and sepsis-induced AKI (SI-AKI) is a cause of the high mortality and morbidity.
Aim: To determine the use of neutrophil gelatinase-related lipocalin (NGAL) and Renal Resistive Index (RRI) in the predicting the development of AKI and mortality in patients with sepsis in the ICU.
Methods: Patients with sepsis who were admitted into the ICU were divided into the AKI and non-AKI groups.